ONO PHARMACEUTICAL CO.,LTD.

February 8, 2017

U.S. Food and Drug Administration Approves Parsabiv™ (Etelcalcetide) to Treat Secondary Hyperparathyroidism in Adult Patients on Hemodialysis

On February 7, 2017, Amgen Inc. (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.

For further information, visit the link below to the website for press release distributed by Amgen.

http://www.amgen.com/media/news-releases/2017/02/fda-approves-amgens-parsabiv-etelcalcetide-first-new-treatment-in-more-than-a-decade-for-secondary-hyperparathyroidism-in-adult-patients-on-hemodialysis/

In Japan, ONO PHARMACEUTICAL CO., LTD. (“ONO”) has exclusive rights to develop and commercialize Parsabiv, in accordance with the license agreement concluded with KAI Pharmaceuticals, Inc., now a wholly-owned subsidiary of Amgen, in September 2011. In Japan, ONO has received a manufacturing and marketing approval of Parsabiv for the treatment of secondary hyperparathyroidism in patients on hemodialysis on December 19, 2016. In Europe, the European Commission (EC) granted Amgen the marketing authorization of Parsabiv™ for the treatment of secondary hyperparathyroidism in adult hemodialysis patients with chronic kidney disease on November 11, 2016.

ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
Public_relations@ono.co.jp